|Videos|December 24, 2019
HER2+ mBC: DESTINY-Breast04 Trial
Author(s)Sponsored Content
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
2
FDA Approves Ibrance Combo for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer
3
Living With Cancer: What the Mariana Trench and Cancer Have in Common
4
The Life I Did Not Expect After Cancer
5